Brookfield Asset Management To Buy Brookfield Property Partners - Quick Facts

Brookfield Asset Management Inc. (BAM, BAM_A.TO) agreed to acquire all of the limited partnership units of Brookfield Property Partners L.P. (BPY, BPY_U.TO) at a value of $18.17 per BPY unit to be completed by way of an Ontario court-approved plan of arrangement. It represents total consideration of $6.5 billion payable to the unitholders of BPY other than Brookfield and its affiliates.

BPY unitholders will have the ability to elect to receive, per BPY unit, $18.17 in cash, 0.3979 of a Brookfield class A limited voting share, or 0.7268 of a BPY preferred unit with a liquidation preference of $25.00 per unit. Pro-ration will be based on a maximum cash consideration of about 50% of the total value of the BPY units , a maximum amount of Brookfield Shares equal to about 42% of the total value of the BPY units, and a maximum amount of BPY preferred units with a liquidation value of about 8% of the total value of the BPY units.

The deal is expected to close in the third quarter of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT